Phibro Animal Health Corp ( (PAHC) ) has released its Q1 earnings. Here is a breakdown of the information Phibro Animal Health Corp presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Phibro Animal Health Corporation is a global leader in animal health and mineral nutrition, providing solutions to enhance the health of farm and companion animals. The company operates primarily in the animal health sector, offering products such as medicated feed additives, nutritional specialties, and vaccines.
Phibro Animal Health Corporation reported a strong start to fiscal 2026 with significant growth in its first-quarter financial results. The company achieved a 40% increase in net sales, reaching $363.9 million, and a substantial rise in net income to $26.5 million, reflecting a $19.6 million increase from the previous year.
Key financial highlights include a 55% increase in Animal Health sales, driven by high demand for medicated feed additives, nutritional specialties, and vaccines. The company also launched Restoris™, a new dental gel for dogs, as part of its strategic investment in animal health innovation. Despite a slight decline in Performance Products sales, Phibro’s overall gross profit rose by 43%, supported by favorable product mix and increased selling prices.
Looking ahead, Phibro has raised its fiscal year 2026 Adjusted EBITDA guidance while maintaining its net sales projections. The company anticipates continued growth, with net sales expected to reach between $1.43 billion and $1.48 billion, and adjusted EBITDA projected to be between $230 million and $240 million, reflecting a 28% growth.
Phibro remains committed to delivering long-term value through strategic investments and innovation in the animal health sector, positioning itself for sustained growth in the coming years.